CRII (OTC BB .58)..here is the back door to the human genome project:
Cell Robotics' Reports Additional Lasette(R) Sales to China And Potentially Large Backlog in Workstation Sales
ALBUQUERQUE, N.M., June 15 /PRNewswire/ -- CELL ROBOTICS INTERNATIONAL INC. (OTC Bulletin Board: CRII - news), the developer of the Lasette®, a needleless laser finger perforator that allows the nearly painless drawing of capillary blood samples by healthcare professionals and by diabetics monitoring their blood glucose levels, today announced that its distributor in China, CA Continental, has ordered an additional 100 Lasettes and 240,000 disposables. CA Continental has also made a verbal commitment to purchase an additional 100 Lasettes and 240,000 disposables before the end of June.
The market pull for the Cell Robotics Research Workstation continues to grow. The company will deliver over $300,000 in workstation sales in the second quarter of 2001 and will enter into the third quarter with a potential backlog, based on quotes, of approximately $1,000,000.
The company is currently working on new enhancements to the existing Workstation. The new Imaging Cell Robotics Workstation will include a sophisticated imaging and quantitative measurement capability along with the availability of a more powerful LaserScissors®.
The increased interest in and sales of the Cell Robotics Workstation can be attributed in part to the following enabling areas within biotechnology. The enormous human genome project defined the individual through the genetic structure. Using the genome as a blueprint, the study of proteins helps explain what can cause or cure diseases. The study of proteins, called proteomics, is a new emphasis area for biology. The Cell Robotics Workstation, through its LaserTweezers® and LaserScissors, allows new ways to study the function and structure of proteins. Understanding proteins is a key to curing such neurological diseases as Multiple Sclerosis, Parkinson's and Alzheimer's.
Another area where the workstation provides increased efficiency is in the production of transgenic animals. These are animals that have human genes inserted into them. For example, transgenic chickens may produce a particular protein in the whites of their eggs. This protein can then be harvested from the egg as a constituent of a drug to treat disease. Once such a transgenic chicken is developed, the Cell Robotics Workstation can be used to create a genetic copy of additional chickens for drug production. Finally, efficiency can also be improved in the laboratory. Scientists can supervise technicians using the Cell Robotics Workstation rather than being required to use their personal expertise to perform detailed operations. For example, technicians can isolate stem cells from such tissues as fat obtained by liposuction for the growing of skin, bone or cartilage.
Dr. Ronald K. Lohrding, President and Chief Executive Officer of the Company, stated, ``The growing sales of our lead product, the Lasette, in the U.S. and abroad, continue to validate our belief in the unique laser technology that helps diabetics to painlessly collect blood samples for daily blood glucose screenings. Due to the recent introduction of the improved Lasette Plus, we have seen increased interest, which may contribute to future sales. We are also very excited about the increasing market demand for our Cell Robotics Workstation from scientists wanting to find more efficient and effective ways to analyze and manipulate cells for various types of research.''
Cell Robotics International, Inc. is a medical products company striving to enhance patient quality-of-life through technology. Cell Robotics develops, sells and markets technologically unique devices that respond to the rapidly increasing market demand for products that offer more effective, safer, and less painful solutions than conventional procedures. Detailed information about the Lasette® and media quality photographs can be found at cellrobotics.com or by calling 505-343-1131. |
